Brief: Inhibikase Therapeutics Completes Enrollment Of Phase 2 Trial Evaluating Risvodetinib In Untreated Parkinson’S Disease
17/06/2024 13:40
June 17 (Reuters) - Inhibikase Therapeutics Inc IKT.O :
* INHIBIKASE THERAPEUTICS COMPLETES ENROLLMENT OF THE PHASE
2
‘201’ TRIAL EVALUATING RISVODETINIB IN UNTREATED PARKINSON’S
DISEASE
* INHIBIKASE THERAPEUTICS INC: EXPECTS TO REPORT TRIAL
RESULTS IN
Q4 OF 2024
Source text for Eikon: ID:nGNX6gD1DP
Further company coverage: IKT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Inhibikase Therapeutics
See all newsBrief: Inhibikase Therapeutics Appoints Scott Wasserman To Board Of Directors
Inhibikase Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Inhibikase Q2 net loss widens on higher R&D, SG&A costs
Inhibikase Therapeutics, Inc. expected to post a loss of 11 cents a share - Earnings Preview
Brief: Inhibikase Therapeutics Prices Public Offering Of 46 Million Shares At $1.45 Per Share